

## Income statement

kSEK	Apr-Jun 2023	Apr-Jun 2022	Jan-Jun 2023	Jan-Jun 2022	Jan-Dec 2022
<b>Net sales</b>	<b>1,138</b>	<b>0</b>	<b>1,138</b>	<b>0</b>	<b>0</b>
Other income	638	3	1,276	12	17
<b>Total income</b>	<b>1,776</b>	<b>3</b>	<b>2,414</b>	<b>12</b>	<b>17</b>
Other external costs	-3,372	-4,709	-5,865	-7,460	-16,323
Personnel costs	-3,160	-2,838	-5,938	-6,115	-11,276
Depreciation of tangible and intangible assets	-304	-329	-606	-650	-1,373
<b>Operating result</b>	<b>-5,060</b>	<b>-7,873</b>	<b>-9,995</b>	<b>-14,213</b>	<b>-28,955</b>
<b>Result from financial items</b>					
Financial net	95	-9	158	46	167
<b>Result after financial items</b>	<b>-4,965</b>	<b>-7,882</b>	<b>-9,837</b>	<b>-14,167</b>	<b>-28,788</b>
<b>RESULT FOR THE PERIOD</b>	<b>-4,965</b>	<b>-7,882</b>	<b>-9,837</b>	<b>-14,167</b>	<b>-28,788</b>
Result per share before and after dilution*	-0.36	-0.57	-0.71	-1.03	-2.09

\*Dilution effect is not calculated when the result is negative

## Balance sheet statement

kSEK	2023-06-30	2022-06-30	2022-12-31
<b>Assets</b>			
Subscribed unpaid capital	0	0	0
<b>Intangible assets</b>			
Patents, licenses, trademarks and similar rights	497	500	624
<b>Tangible assets</b>			
Equipment & tools	7,823	11,776	8,246
<b>Total non-current assets</b>	<b>8,320</b>	<b>12,276</b>	<b>8,870</b>
<b>Current assets</b>			
<b>Short-term receivables</b>			
Other receivables	364	576	496
Prepaid expenses & accrued income	1,368	1,601	968
<b>Total short-term receivables</b>	<b>1,732</b>	<b>2,177</b>	<b>1,464</b>
Cash & cash equivalents	14,583	36,647	22,951
<b>Total current assets</b>	<b>16,315</b>	<b>38,824</b>	<b>24,415</b>
<b>TOTAL ASSETS</b>	<b>24,635</b>	<b>51,100</b>	<b>33,285</b>
<b>Equity &amp; liabilities</b>			
<b>Equity</b>			
<b>Restricted equity</b>			
Share capital	2,301	2,301	2,301
<b>Total restricted equity</b>	<b>2,301</b>	<b>2,301</b>	<b>2,301</b>
<b>Unrestricted equity</b>			
Share premium fund	105,400	105,431	105,400
Retained earnings	-78,181	-49,860	-49,612
Result of the period	-9,837	-14,167	-28,788
<b>Total unrestricted capital</b>	<b>17,382</b>	<b>41,404</b>	<b>27,000</b>
<b>Total equity</b>	<b>19,683</b>	<b>43,705</b>	<b>29,301</b>
<b>Debt</b>			
<b>Long-term debt</b>			
Loans	571	1,143	857
<b>Short-term debt</b>			
Account payables	1,262	3,365	978
Short-term loans	571	571	571
Tax debt	0	18	0
Other short-term debt	311	603	416
Accrued expenses and deferred income	2,237	1,695	1,162
<b>Total short-term debt</b>	<b>4,381</b>	<b>6,256</b>	<b>3,127</b>
<b>TOTAL EQUITY &amp; LIABILITIES</b>	<b>24,635</b>	<b>51,100</b>	<b>33,285</b>

## Changes in equity

kSEK	Restricted equity	Unrestricted equity	Retained earnings	Result of the period	Total equity
	Share capital	Share premium fund			
<b>Opening balance 2022-01-01</b>	1,834	77,900	-28,867	-21,136	29,731
Appropriations of net result			-21,136	21,136	0
Result of the period				-28,788	-28,788
<b>Transactions with shareholders</b>					
Share issue	467	27,584			28,051
Share issue costs		-84			-84
Share related remunerations			391		391
<b>Closing balance 2022-12-31</b>	<b>2,301</b>	<b>105,400</b>	<b>-49,612</b>	<b>-28,788</b>	<b>29,301</b>
<b>Opening balance 2023-01-01</b>	<b>2,301</b>	<b>105,400</b>	<b>-49,612</b>	<b>-28,788</b>	<b>29,301</b>
Appropriations of net result			-28,788	28,788	0
Result of the period				-9,837	-9,837
<b>Transactions with shareholders</b>					
Share issue					0
Share issue costs					0
Share related remunerations			219		219
<b>Closing balance 2023-06-30</b>	<b>2,301</b>	<b>105,400</b>	<b>-78,181</b>	<b>-9,837</b>	<b>19,683</b>

## Cash flow statement

kSEK	Apr-Jun 2023	Apr-Jun 2022	Jan-Jun 2023	Jan-Jun 2022	Jan- Dec 2022
<b>Cash flow from operating activities</b>					
Operating result	-5,060	-7,874	-9,995	-14,213	-28,955
Ingoing interest	90	21	180	38	163
Paid interest	-26	-23	-52	-47	-94
<b>Adjustments for items that is not included in the cash flow</b>					
Share related remunerations	100	123	219	143	392
Currency exchange	31	-7	30	55	99
Depreciations & disposals	304	1,190	606	1,511	5,409
<b>Cash flow from operating activities before changes in working capital</b>	<b>-4,561</b>	<b>-6,570</b>	<b>-9,012</b>	<b>-12,513</b>	<b>-22,986</b>
<b>Cash flow from changes in working capital</b>					
Changes in operating receivables	-408	23	-268	12,069	12,781
Changes in operating debt	585	574	968	226	-3,186
<b>Cash flow from operating activities</b>	<b>-4,384</b>	<b>-5,973</b>	<b>-8,312</b>	<b>-218</b>	<b>-13,391</b>
<b>Investing activities</b>					
Acquisitions of non-current assets	-56	-1,614	-56	-3,406	-3,898
<b>Cash flow from investment activities</b>	<b>-56</b>	<b>-1,614</b>	<b>-56</b>	<b>-3,406</b>	<b>-3,898</b>
<b>Financing activities</b>					
Share issue (LTI 2018/21)	0	0	0	0	0
Warrants (LTI 2021/24)	0	0	0	0	0
Share issue	0	0	0	28,051	28,051
Share issue costs	0	0	0	-53	-84
<b>Cash flow from financing activities</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>27,998</b>	<b>27,967</b>
<b>Cash flow from the period</b>	<b>-4,440</b>	<b>-7,587</b>	<b>-8,368</b>	<b>24,374</b>	<b>10,678</b>
<b>Opening balance cash &amp; cash equivalents</b>	<b>19,023</b>	<b>44,234</b>	<b>22,951</b>	<b>12,273</b>	<b>12,273</b>
<b>CLOSING BALANCE CASH &amp; CASH EQUIVALENTS</b>	<b>14,583</b>	<b>36,647</b>	<b>14,583</b>	<b>36,647</b>	<b>22,951</b>

## Note 1 Accounting standards

Ziccum AB (publ) reports in accordance with the Swedish Annual Accounts Act and the Swedish Accounting Standards Board's general advice BFAR 2012:1 (K3).

The company's accounting principles are described in the company's annual report for 2022.

Amounts are expressed in kSEK, which in this report refers to thousands of Swedish kronor.

Amounts in parentheses refer to comparative figures from the previous year, if nothing else is stated.

## Note 2 Pledged assets and contingent liabilities

Pledged assets	2023-06-30	2022-12-31
Company mortgage	2,000	2,000

## Note 3 Changes in equity

Date	Transaction	Number of serie B	Share capital	Quota-value	Subscription-course	Total invested capital (SEK)
5 Apr 17	Formation	500	50,000	1.00	1.00	50,000
29 May 17	Share issue	500	50,000	1.00	1.00	50,000
31 Dec 17	Conditional shareholder contribution*	-	-	-	-	1,996,622
25 Apr 18	Bond issue	-	400,000	1.00	-	-
27 Apr 18	Split	2,999,000	-	0.17	-	-
19 Oct 18	Share issue	3,000,000	500,000	0.17	5.26	15,776,962
14 Jan 20	Share issue	1,389,385	231,564	0.17	10.00	13,893,850
6 Jul 20	Share issue	2,216,815	369,469	0.17	17.50	38,794,263
15 Jun 21	Share issue (LTI 2018/21)	200,000	33,334	0.17	11.00	2,200,000
21 Dec 21	Share issue	1,199,856	199,976	0.17	11.00	13,198,416
18 Jan 22	Share issue	2,800,086	466,680	0.17	11.00	30,800,946
<b>Total</b>		<b>13,806,142</b>	<b>2,301,023</b>			<b>116,761,059</b>

\* Inhalation Sciences Sweden AB did in 2017 provide conditional shareholder contributions amounting to 1 996 622 SEK (cash 0.3 mSEK and reverse loans arising in connection with the acquisition of intangible assets by the parent company converted to shareholder contributions amounting to approximately 1.7 mSEK).

## Note 4 Share related incentive programs

On June 30 2023, the company has four ongoing option programs.

- ▶ At the Annual General Meeting on April 27 2021, it was decided to introduce a long-term incentive program by issuing warrants to the Board of Directors (**LTI 2021/2024**), as well as a long-term incentive program for the company's employees consisting of employee stock options (**LTI 2021:1**).
- ▶ At the Annual General Meeting on April 28 2022, it was decided to implement a long-term incentive program for the company's Board of Directors (**LTI 2022:1**) and employees (**LTI 2022:2**) consisting of employee stock options.

None of the options entail the right to a dividend.

Based on the existing number of shares and options that is registered in the company as of 30 June 2023, the dilution as a result of the incentive programs, assuming that all warrants are exercised for new subscription of shares, is approximately 3% of the number of shares and votes.

### LTI 2021/24

The exercise price per share for LTI 2021/2024 amounts to SEK 28.8 and subscription can take place during the period from 1 May 2024 to 31 May 2024. The incentive program means that participants are offered to subscribe warrants at market value calculated according to the Black-Scholes valuation model.

A prerequisite for participation in the incentive program is that the participant has entered into a pre-purchase agreement with Ziccum, whereby Ziccum, with certain exceptions, reserves the right to repurchase warrants if the board member's assignment in Ziccum ends or if the participant wishes to transfer the options before the warrants can be exercised.

The Board was offered to acquire a maximum of 9 200 warrants each and all chose to acquire the maximum number, which resulted in a total of 46 000 warrants being issued.



## LTI 2021:1

LTI 2021:1 runs for three years and means that participants are granted employee stock options free of charge that give the right to acquire shares in Ziccum at a subscription price corresponding to the share's quota value. Each employee stock option gives the right to subscribe for a new share in Ziccum, alternatively up to 40% of the number in synthetic options that give the right to cash compensation instead of shares. Each synthetic option entitles the participant to receive a cash payment corresponding to the value of a share at the time of payment.

The options will be expensed as personnel costs over a period of three years, without affecting the company's cash flow. If employee stock options are exercised, LTI 2021:1 will also entail costs in the form of social security contributions.

Social security contributions will be expensed in the income statement during a period of three years. The company intends to hedge the entire cost of social security contributions through an issue of warrants, which may be exercised by a financial intermediary in connection with the exercise of the employee stock options. If the company chooses to implement such hedging measures, the social security contributions will not affect the company's cash flow.

	<b>Number of employee stock options</b>
<b>Ingoing balance 1 Jan 2022</b>	35,728
Reversed	-16,364
<b>Outgoing balance 31 Dec 2022</b>	<b>19,364</b>

  

	<b>Number of employee stock options</b>
<b>Ingoing balance 1 Jan 2023</b>	19,364
Reversed	-4,545
<b>Outgoing balance 30 June 2023</b>	<b>14,819</b>

During 2023, LTI 2021:1 have affected the reporting period result with totally 55 kSEK in costs, of which costs of 11 kSEK relates to social security contributions.

## LTI 2022:1 & LTI 2022:2

LTI 2022:1 (for the Board of directors) and LTI 2022:2 (for the employees) runs for three years and means that participants are granted employee stock options free of charge that give the right to acquire shares in Ziccum at a subscription price corresponding to the share's quota value. Each employee stock option gives the right to subscribe for a new share in Ziccum, alternatively up to 40% of the number in synthetic options that give the right to cash compensation instead of shares. Each synthetic option entitles the participant to receive a cash payment corresponding to the value of a share at the time of payment.

The options will be expensed as personnel costs over a period of three years, without affecting the company's cash flow. If employee stock options are exercised, LTI 2022:1 and LTI 2022:2 will also entail costs in the form of social security contributions.

Social security contributions will be expensed in the income statement during a period of three years. The company intends to hedge the entire cost of social security contributions through an issue of warrants, which may be exercised by a financial intermediary in connection with the exercise of the employee stock options. If the company chooses to implement such hedging measures, the social security contributions will not affect the company's cash flow.

Number of employee stock options	2022:1	2022:2	Total
<b>Opening balance 1 Jan 2022</b>	<b>0</b>	<b>0</b>	<b>0</b>
Issued	165,000	226,000	391,000
<b>Ending balance 31 Dec 2022</b>	<b>165,000</b>	<b>226,000</b>	<b>391,000</b>
<b>Opening balance 1 Jan 2023</b>	<b>165,000</b>	<b>226,000</b>	<b>391,000</b>
Reversed	-66,000	-15,000	-81,000
<b>Ending balance 30 Jun 2023</b>	<b>99,000</b>	<b>211,000</b>	<b>310,000</b>

During 2023, LTI 2022:1 and LTI 2022:2 have affected the reporting period result with totally 538 kSEK in costs, of which 154 kSEK relates to social security contributions.



## Note 5 Definitions of key figures

	Apr-Jun 2023	Apr-Jun 2022	Jan-Jun 2023	Jan-Jun 2022	Jan-Dec 2022
<b>Cash flow per share</b>					
Cash flow from the period, kSEK	-4,440	-7,587	-8,368	24,372	10,678
Average number of shares	13,806,142	13,806,142	13,806,142	13,203,882	13,675,727
<b>Cash flow per share (SEK)</b>	<b>-0.32</b>	<b>-0.55</b>	<b>-0.61</b>	<b>1.85</b>	<b>1</b>
<b>Equity per share</b>					
Equity, kSEK	19,683	43,705	19,683	43,705	29,301
Number of shares at the end of the period	13,806,142	13,806,142	13,806,142	13,806,142	13,806,142
<b>Equity per share (SEK)</b>	<b>1.43</b>	<b>3.17</b>	<b>1.43</b>	<b>3.17</b>	<b>2</b>
<b>Equity ratio</b>					
Equity, kSEK	19,683	43,705	19,683	43,705	29,301
Total equity & debt, kSEK	24,635	51,100	24,635	51,100	33,285
<b>Equity ratio %</b>	<b>80%</b>	<b>86%</b>	<b>80%</b>	<b>86%</b>	<b>1</b>